Novo Nordisk A/S (NVO) rose 0.7% in late trading on Wednesday. The company reported mixed third-quarter results and revised its growth expectations downward. Reports indicate that Novo Nordisk has increased its offer for Metsera to up to $10 billion, surpassing Pfizer's $8.1 billion bid. During ongoing antitrust and merger litigation, a judge rejected Pfizer's attempt to block Novo Nordisk's acquisition efforts.